Welcome to the Janssen Oncology ASCO Newsroom
I have the pleasure of leading a talented global team of scientists and professionals focused on a lofty yet achievable vision — the elimination of cancer. Our work spans end-to-end oncology research and development, from discovery through full clinical development, applying our deep scientific expertise, and leveraging strategic partnerships to access and advance innovative targets and platforms.
Visit this site to follow along with updates from the 2021 ASCO Annual Meeting and the 2021 European Hematology Association (EHA) Virtual Congress. These are important meetings for our researchers and our commitment to advancing science, and for the global oncology community.
During these meetings, we'll report results and clinical data from our robust oncology pipeline and portfolio. In fact, more than 50 accepted abstracts and 13 oral presentations will highlight compelling new data from 10 approved and investigational products in multiple myeloma, leukemia, light chain amyloidosis, lung cancer, prostate cancer and bladder cancer, from across a multitude of company-sponsored and collaborative studies.
On behalf of the entire team, thank you for your interest in Janssen Oncology. We’re looking forward to contributing to the science and sessions of ASCO and EHA, virtually. And until we can connect again in person, wishing you all the best and continued good health as together we aim to transform the lives of patients facing a cancer diagnosis.
Peter Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head, Oncology
Janssen Research & Development, LLC
President, Janssen Oncology
Janssen Pharmaceuticals, Inc.
Dr. Alexander Spira Discusses Advances in Non-Small Cell Lung Cancer (NSCLC)
Dr. Paolo Ghia Discusses Advances in Chronic Lymphocytic Leukemia (CLL)
Dr. Saad Usmani Discusses Advances in Multiple Myeloma (MM)